The DNA methylation machinery as a target for anticancer therapy.
DNA methylation is now recognized as an important mechanism regulating different functions of the genome; gene expression, replication, and cancer. Different factors control the formation and maintenance of DNA methylation patterns. The level of activity of DNA methyltransferase (MeTase) is one factor. Recent data suggest that some oncogenic pathways can induce DNA MeTase expression, that DNA MeTase activity is elevated in cancer, and that inhibition of DNA MeTase can reverse the transformed state. What are the pharmacological consequences of our current understanding of DNA methylation patterns formation? This review will discuss the possibility that DNA MeTase inhibitors can serve as important pharmacological and therapeutic tools in cancer and other genetic diseases.
Szyf
M
M
Department of Pharmacology and Therapeutics, McGill University, Montreal, Canada.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001482:Base Composition; D001667:Binding, Competitive; D019175:DNA Methylation / Q000187:drug effects*; D015254:DNA Modification Methylases / Q000235:genetics* / Q000378:metabolism; D004261:DNA Replication / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects* / Q000235:genetics; D015316:Genetic Therapy; D016678:Genome; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D015398:Signal Transduction / Q000235:genetics; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism
D000970:Antineoplastic Agents; D014157:Transcription Factors; D015254:DNA Modification Methylases